CervoMed Secures $10 Million to Advance Brain Disease Pipeline
BOSTON, June 18, 2026 CervoMed Inc., a clinical-stage biotechnology company focused on developing therapies for age-related neurological disorders, has...
Neurodegeneration
Advertisement
Biogen Reports Breakthrough Tau Therapy Alzheimer Data
CAMBRIDGE, Mass., May 14, 2026 Biogen Inc. has announced promising topline results from its Phase 2 CELIA study evaluating...
Neuraly Inc Advances NLY01 Phase 2 MS Trial
GAITHERSBURG, Md., United States – May 2026 Neuraly Inc. has announced that the first patient has been dosed in...
IGC Pharma Strengthens CALMA Trial Through Caregiver Outreach
POTOMAC, Maryland, April 28, 2026 IGC Pharma, Inc. has announced expanded caregiver engagement efforts as its Phase 2 CALMA...
Tiziana Life Sciences Nasal Therapy Boosts Brain Health
Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...
Advertisements
FDA Clears First-in-Class Vectorized Antibody ALS Trial With VTx-002
Amsterdam, The Netherlands, and Boston, MA — January 8, 2026 — VectorY Therapeutics announced that the U.S. Food and...
AC Immune’s Phase 2 Data Shows Promise in Slowing Parkinson’s Progression
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
China Adds LEQEMBI to Insurance List for Early Alzheimer’s
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
Zervimesine Phase 3 Plan Advances Alzheimer’s Drug Strategy
Purchase, N.Y. — December 1, 2025 — Cognition Therapeutics has unveiled its Phase 3 registrational plan for Zervimesine (CT1812)...
Elanco Leader Joins Neurizon to Boost ALS Drug Program
MELBOURNE, Australia – Nov. 26, 2025 — Neurizon Therapeutics (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotech firm...
Advertisement
